Expression and its clinical significance of Musashi2 in different molecular subtypes of breast invasive ductal carcinoma

doi:10.11958/20220121

Abstract

Abstract:

Objective To investigate the expression of Musashi2 in different molecular subtypes of breast invasive ductal carcinoma and its correlation with clinical and molecular pathological features and prognosis. Methods The clinicopathological data of 125 patients with breast invasive ductal carcinoma were collected. The expression of Musashi2, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2) and Ki67 expression in tumor tissues were detected by immunohistochemistry. Fluorescence in situ hybridization (FISH) was further detected in patients with a "++" HER2 immunohistochemistry results. According to the test results, molecular subtyping was performed. The relationship between Musashi2 expression and its clinical and molecular pathological characteristics and prognosis was analyzed in breast invasive ductal carcinoma with different molecular subtypes. Results The positive rates of Musashi2 in invasive ductal carcinoma and ductal carcinoma in situ were significantly higher than those in normal breast tissues (P<0.01). The positive rates in the Luminal A and the Luminal B groups were significantly higher than that in the HER2+ and triple-negative type groups (P<0.05). The positive rates of Musashi2 in early stage (Ⅰand Ⅱ) were significantly higher than those in the late stage (Ⅲ and Ⅳ, P<0.05). However, there were no significant differences in Musashi2 expression levels between different ages, tumor diameters, histological grades, vascular involvement and lymph node metastasis of invasive ductal carcinoma of breast (P>0.05). The expression level of Musashi2 was positively correlated with ER and PR (r = 0.408, r = 0.405), but no relationship with HER2 and Ki67 (P>0.05). Kaplan-Meier survival analysis showed that there was no significant difference in disease-free survival between the Musashi2 positive group and the Musashi2 negtive group (67 months±12 months vs. 63 months±15 months, Log-rank χ²=0.752, P>0.05). Conclusion The expression of Musashi2 protein in breast invasive ductal carcinoma is related to its molecular subtype and TNM stage. The higher expression of musashi2 indicates a lower degree of malignant.

Key words: breast neoplasms, carcinoma,ductal,breast, pathology,clinical, Musashi2

CLC Number:

R737.9

Figures/Tables 4

References 23

[1]	OKANO H, IMAI T, OKABE M. Musashi:a translational regulator of cell fate[J]. J Cell Sci, 2002, 115(Pt7):1355-1359. doi: 10.1242/jcs.115.7.1355.
[2]	李宇, 王鹏, 贾垚, 等. Msi2在上皮细胞肿瘤中的作用及临床价值[J]. 现代医学, 2017, 45(8):1167-1170.
	LI Y, WANG P, JIA Y, et al. Clinical value and role of Msi2 in epithelial tumor[J]. Modern Medical Journal, 2017, 4(8):1167-1170. doi: 10.3969/j.issn.1671-7562.2017.08.026.
[3]	李捷, 刘紫蒙, 郑一琼, 等. 乳腺浸润性导管癌组织IRS1、PRSS3蛋白表达与磷酸化蛋白激酶B表达和预后的关系研究[J]. 现代生物医学进展, 2021, 21(24):4617-4622.
	LI J, LIU Z M, ZHENG Y Q, et al. Relationship research between the IRS1,PRSS3 protein expression and phosphorylated protein kinase B expression and prognosis in breast invasive ductal carcinoma[J]. Progress in Modern Biomedicine, 2021, 21(24):4617-4622. doi: 10.13241/j.cnki.pmb.2021.24.003.
[4]	马建萍, 马芬兰. 不同分子分型乳腺癌的临床病理特征及预后的关系[J]. 实用癌症杂志, 2017, 32(12):2041-2044.
	MA J P, MA F L. Clinicopathological features and prognosis of different molecular types of breast cancer[J]. The Practical Journal of Cancer, 2017, 32(12):2041-2044. doi: 10.3969/j.issn.1001-5930.2017.12.039.
[5]	LAKHANI S R, ELLIS I O, SCHNITT S J, et al. WHO classification of tumours of the breast[M]. 4th ed. Lyon: International Agency for Research on Cancer (IARC) press, 2012:34-38.
[6]	GIULIANO A E, EDGE S B, HORTOBAGYI G N. Eighth edition of the AJCC cancer staging manual:breast cancer[J]. Ann Surg Oncol, 2018, 25(7):1783-1785. doi: 10.1245/s10434-018-6486-6.
[7]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)[J]. 中国癌症杂志, 2015, 25(9):692-754.
	Chinese Anti-Cancer Association, Committee of Breast Cancer Society. Guidelines and norms for diagnosis and treatment of breast cancer of Chinese Anti-cancer Association (2015 edition)[J]. China Oncol, 2015, 25(9):692-754. doi: 10.3969/j.issn.1007-3969.2015.09.010.
[8]	《乳腺癌HER2检测指南2014版》编写组. 乳腺癌HER2检测指南(2014版)[J]. 中华病理学杂志, 2014, 43(4):262-267.
	“Breast cancer HER2 detection gudelines (2014 edition)” Compilling Group. Breast cancer HER2 detection guidelines (2014 edition)[J]. Chin J Pathol, 2014, 43(4):262-267. doi: 10.3760/cma.j.issn.0529-5807.2014.04.012.
[9]	KUDINOV A E, KARANICOLAS J, GOLEMIS E A, et al. Musashi RNA-binding proteins as cancer drivers and novel therapeutic targets[J]. Clin Cancer Res, 2017, 23(9):2143-2153. doi: 10.1158/1078-0432.CCR-16-2728.
[10]	王小刚, 刘静, 郭庚, 等. MSI2生物学特性的研究进展[J]. 国际遗传学杂志, 2017, 40(4):228-232.
	WANG X G, LIU J, GUO G, et al. Research progress of the biological characteristics of MSI2[J]. International Journal of Genetics, 2017, 40(4):228-232.doi: 10.3760/cma.j.issn.1673-4386.2017.04.008.
[11]	DAS CHAGAS P F, BARONI M, BRASSESCO M S, et al. Interplay between the RNA binding-protein Musashi and developmental signaling pathways[J]. J Gene Med, 2020, 22(1):e3136. doi: 10.1002/jgm.3136.
[12]	LIU Y, FAN Y, WANG X, et al. Musashi-2 is a prognostic marker for the survival of patients with cervical cancer[J]. Oncol Lett, 2018, 15(4):5425-5432. doi: 10.3892/ol.2018.8077.
[13]	ZHAO J, ZHANG Y, LIU X S, et al. RNA-binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression[J]. Cancer Sci, 2020, 111(2):369-382. doi: 10.1111/cas.14280.
[14]	YANG Z, LI J, SHI Y, et al. Increased musashi 2 expression indicates a poor prognosis and promotes malignant phenotypes in gastric cancer[J]. Oncol Lett, 2019, 17(3):2599-2606. doi: 10.3892/ol.2019.9889.
[15]	SHENG W, DONG M, CHEN C, et al. Musashi2 promotes the development and progression of pancreatic cancer by down-regulating Numb protein[J]. Oncotarget, 2017, 8(9):14359-14373. doi: 10.18632/oncotarget.8736.
[16]	张苏杰, 殷华奇, 叶雄俊, 等. Musashi-2在恶性肿瘤发生发展及诊疗靶点中的作用[J]. 协和医学杂志, 2017, 8(4):289-293.
	ZHANG S J, YIN H Q, YE X J, et al. Role of Musashi-2 in the occurrence and development and as the diagnostic and therapeutic target of malignant tumours[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4):289-293. doi: 10.3969/j.issn.1674-9081.2017.05.018.
[17]	EMADI-BAYGI M, NIKPOUR P, MOHAMMAD-HASHEM F, et al. MSI2 expression is decreased in grade II of gastric carcinoma[J]. Pathol Res Pract, 2013, 209(11):689-691. doi: 10.1016/j.prp.2013.07.008.
[18]	王琳, 沈佳丽, 熊世双, 等. JAG1和Notch3在乳腺癌组织中的表达及预后价值[J]. 临床肿瘤学杂志, 2020, 25(1):13-19.
	WANG L, SHEN J L, XIONG S S, et al. Expression of JAG1 and Notch3 in breast cancer tissues and their prognostic value[J]. Chinese Clinical Oncology, 2020, 25(1):13-19. doi: 10.3969/j.issn.1009-0460.2020.01.003.
[19]	SORLIE T, TIBSHIRANI R, PARKER J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets[J]. Proc Natl Acad Sci U S A, 2003, 100(14):8418-8423. doi: 10.1073/pnas.0932692100.
[20]	KATZ Y, LI F, LAMBERT N J, et al. Musashi proteins are post-transcriptional regulators of the epithelial-luminal cell state[J]. Elife, 2014, 3:e03915. doi: 10.7554/eLife.03915.
[21]	李菲菲. Musashi在乳腺发育和肿瘤发生中的功能与分子作用机制[D]. 北京: 中国农业大学, 2016.
	LI F F. The function and molecular mechanism of Musashi on mammary gland development and tumorigenesis[D]. Beijing: China Agricultural University, 2016.
[22]	张莹, 任占平, 张芫. Ki-67表达与乳腺癌分子分型及临床病理特征的关系[J]. 临床与实验病理学杂志, 2014, 30(11):1220-1223.
	ZHANG Y, REN Z P, ZHANG Y. Relationship between the expression of Ki-67 and molecular classification and clinical pathological features in breast cancerr[J]. J Clin Exp Pathol, 2014, 30(11):1220-1223. doi: 10.13315/j.cnki.cjcep.2014.11.005.
[23]	KANG M H, JEONG K J, KIM W Y, et al. Musashi RNA-binding protein 2 regulates estrogen receptor 1 function in breast cancer[J]. Oncogene, 2017, 36(12):1745-1752. doi: 10.1038/onc.2016.327.

临床病理特征		n	Musashi2阳性	χ²
年龄（岁）	≤50	77	43（55.84）	0.075
	>50	48	28（58.33）	0.075
肿瘤直径（cm）	<2	50	32（64.00）	1.858
	2~5	66	34（51.52）
	>5	9	5（55.56）
脉管受累	否	84	46（54.76）	0.434
	是	41	25（60.98）	0.434
淋巴结转移	阴性	53	33（62.26）	1.120
	阳性	72	38（52.78）	1.120
TNM分期	早期	85	54（63.53）	4.902^＊
	晚期	40	17（42.50）	4.902^＊
组织学分级	Ⅰ+Ⅱ	101	61（60.40）	2.772
	Ⅲ	24	10（41.67）	2.772

临床病理特征		n	Musashi2阳性	χ²
年龄（岁）	≤50	77	43（55.84）	0.075
	>50	48	28（58.33）	0.075
肿瘤直径（cm）	<2	50	32（64.00）	1.858
	2~5	66	34（51.52）
	>5	9	5（55.56）
脉管受累	否	84	46（54.76）	0.434
	是	41	25（60.98）	0.434
淋巴结转移	阴性	53	33（62.26）	1.120
	阳性	72	38（52.78）	1.120
TNM分期	早期	85	54（63.53）	4.902^＊
	晚期	40	17（42.50）	4.902^＊
组织学分级	Ⅰ+Ⅱ	101	61（60.40）	2.772
	Ⅲ	24	10（41.67）	2.772

项目		n	Musashi2阳性	χ²	r
HER-2	阴性	78	46（58.97）	0.400	-0.057
	阳性	47	25（53.19）	0.400	-0.057
ER	阴性	36	9（25.00）	20.837^＊＊	0.408^＊
	阳性	89	62（69.66）	20.837^＊＊	0.408^＊
PR	阴性	42	12（28.57）	20.541^＊＊	0.405^＊
	阳性	83	59（71.08）	20.541^＊＊	0.405^＊
Ki67	≤14%	29	20（68.97）	2.278	-0.135
	>14%	96	51（53.13）	2.278	-0.135

项目		n	Musashi2阳性	χ²	r
HER-2	阴性	78	46（58.97）	0.400	-0.057
	阳性	47	25（53.19）	0.400	-0.057
ER	阴性	36	9（25.00）	20.837^＊＊	0.408^＊
	阳性	89	62（69.66）	20.837^＊＊	0.408^＊
PR	阴性	42	12（28.57）	20.541^＊＊	0.405^＊
	阳性	83	59（71.08）	20.541^＊＊	0.405^＊
Ki67	≤14%	29	20（68.97）	2.278	-0.135
	>14%	96	51（53.13）	2.278	-0.135